Matches in SemOpenAlex for { <https://semopenalex.org/work/W3042361689> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W3042361689 endingPage "482" @default.
- W3042361689 startingPage "477" @default.
- W3042361689 abstract "Objectives: This study aimed to investigate the efficacy and safety of nilotinib as the first-line treatment for patients with chronic myelogenous leukemia (CML) and analyze the factors affecting the realization of the major molecular response. Methods: A retrospective study was conducted on 86 newly diagnosed CML patients from the Affiliated Cancer Hospital of Zhengzhou University from January 2014 to June 2017, who were using nilotinib 300 mg, twice a day, as the first-line treatment. There were 49 males and 37 females. Results: At 12 months, the MMR, MR4, and MR4.5 rates were 59.3%, 22.1%, and 15.1%, respectively. At 24 months, the MMR, MR4, and MR4.5 rates were 76.2%, 44.0%, and 27.4%, respectively.The median follow-up time was 42 months (range, 21-66 months) . The median progression-free survival time (PFS) was 42 months (range, 9-66 months) at a PFS rate of 93%. The time required for BCR-ABL transcript to decrease by half compared with the diagnosis was defined as the halving time (HT) . HT was the influencing factor of the 12-month MMR (OR=0.896, P<0.001) and MR4.5 (OR=0.377, P=0.003) . The most common non-hematologic adverse reactions were rash (37.2%) and headache (32.6%) , and most were grade 1/2. The most common hematologic adverse reactions were mainly neutropenia (27.9%) and thrombocytopenia (32.4%) . Conclusion: Nilotinib was an effective and safe first-line treatment for CML patients. HT ≤ 13.68 days is protective factor for long-term progression-free survival.目的： 探讨尼洛替尼一线治疗慢性髓性白血病（CML）的疗效及安全性，并分析影响实现主要分子学反应的因素。 方法： 回顾性分析郑州大学附属肿瘤医院2014年1月至2017年6月收治的86例新诊断为CML的患者，均接受尼洛替尼300 mg每日两次作为一线治疗，其中男性49例，女性37例。 结果： 12个月时获主要分子学反应（MMR）、分子学反应4（MR4）、分子学反应4.5（MR4.5）的患者比例分别为59.3%、22.1%、15.1%；24个月时，获MMR、MR4、MR4.5的患者比例分别为76.2%、44.0%、27.4%。中位随访42（21~66）个月，中位无进展生存（PFS）时间为42（9~66）个月，PFS率为93%。BCR-ABL(IS)融合基因较诊断时下降一半所需要的时间定义为减半时间（HT），HT是CML患者12个月能否达到MMR（OR=0.896，P<0.001）及MR4.5（OR=0.377，P=0.003）的影响因素。非血液学不良反应中最常见的为皮疹（37.2%）和头痛（32.6%），大多数为1/2级，血液学不良反应主要为中性粒细胞减少（27.9%）和血小板减少（32.4%）。 结论： 尼洛替尼一线治疗CML具有较优的有效性和安全性，HT≤13.68 d可能是长期无进展生存的保护因素。." @default.
- W3042361689 created "2020-07-23" @default.
- W3042361689 creator A5002895102 @default.
- W3042361689 creator A5014270790 @default.
- W3042361689 creator A5037844704 @default.
- W3042361689 creator A5053355595 @default.
- W3042361689 creator A5072453373 @default.
- W3042361689 creator A5090241332 @default.
- W3042361689 date "2020-06-14" @default.
- W3042361689 modified "2023-09-28" @default.
- W3042361689 title "[Efficacy of nilotinib in the first-line treatment of chronic myeloid leukemia and the analysis of factors affecting molecular responses]." @default.
- W3042361689 cites W1818590273 @default.
- W3042361689 cites W1980571402 @default.
- W3042361689 cites W1997730029 @default.
- W3042361689 cites W2014173159 @default.
- W3042361689 cites W2021648831 @default.
- W3042361689 cites W2022260454 @default.
- W3042361689 cites W2057827171 @default.
- W3042361689 cites W2061440903 @default.
- W3042361689 cites W2064367288 @default.
- W3042361689 cites W2091005492 @default.
- W3042361689 cites W2260921597 @default.
- W3042361689 cites W2397234997 @default.
- W3042361689 cites W2592060299 @default.
- W3042361689 cites W2619264359 @default.
- W3042361689 cites W2750206713 @default.
- W3042361689 cites W2766187515 @default.
- W3042361689 cites W2891716460 @default.
- W3042361689 cites W2914915521 @default.
- W3042361689 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2020.06.007" @default.
- W3042361689 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7378290" @default.
- W3042361689 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32654460" @default.
- W3042361689 hasPublicationYear "2020" @default.
- W3042361689 type Work @default.
- W3042361689 sameAs 3042361689 @default.
- W3042361689 citedByCount "0" @default.
- W3042361689 crossrefType "journal-article" @default.
- W3042361689 hasAuthorship W3042361689A5002895102 @default.
- W3042361689 hasAuthorship W3042361689A5014270790 @default.
- W3042361689 hasAuthorship W3042361689A5037844704 @default.
- W3042361689 hasAuthorship W3042361689A5053355595 @default.
- W3042361689 hasAuthorship W3042361689A5072453373 @default.
- W3042361689 hasAuthorship W3042361689A5090241332 @default.
- W3042361689 hasConcept C126322002 @default.
- W3042361689 hasConcept C197934379 @default.
- W3042361689 hasConcept C2776694085 @default.
- W3042361689 hasConcept C2776960273 @default.
- W3042361689 hasConcept C2777063308 @default.
- W3042361689 hasConcept C2777413986 @default.
- W3042361689 hasConcept C2777583451 @default.
- W3042361689 hasConcept C2778461978 @default.
- W3042361689 hasConcept C2778570526 @default.
- W3042361689 hasConcept C2778729363 @default.
- W3042361689 hasConcept C71924100 @default.
- W3042361689 hasConcept C90924648 @default.
- W3042361689 hasConceptScore W3042361689C126322002 @default.
- W3042361689 hasConceptScore W3042361689C197934379 @default.
- W3042361689 hasConceptScore W3042361689C2776694085 @default.
- W3042361689 hasConceptScore W3042361689C2776960273 @default.
- W3042361689 hasConceptScore W3042361689C2777063308 @default.
- W3042361689 hasConceptScore W3042361689C2777413986 @default.
- W3042361689 hasConceptScore W3042361689C2777583451 @default.
- W3042361689 hasConceptScore W3042361689C2778461978 @default.
- W3042361689 hasConceptScore W3042361689C2778570526 @default.
- W3042361689 hasConceptScore W3042361689C2778729363 @default.
- W3042361689 hasConceptScore W3042361689C71924100 @default.
- W3042361689 hasConceptScore W3042361689C90924648 @default.
- W3042361689 hasIssue "6" @default.
- W3042361689 hasLocation W30423616891 @default.
- W3042361689 hasOpenAccess W3042361689 @default.
- W3042361689 hasPrimaryLocation W30423616891 @default.
- W3042361689 hasRelatedWork W10263580 @default.
- W3042361689 hasRelatedWork W10386318 @default.
- W3042361689 hasRelatedWork W11313001 @default.
- W3042361689 hasRelatedWork W14327771 @default.
- W3042361689 hasRelatedWork W17437393 @default.
- W3042361689 hasRelatedWork W21174161 @default.
- W3042361689 hasRelatedWork W2731378 @default.
- W3042361689 hasRelatedWork W3489739 @default.
- W3042361689 hasRelatedWork W9510098 @default.
- W3042361689 hasRelatedWork W9829739 @default.
- W3042361689 hasVolume "41" @default.
- W3042361689 isParatext "false" @default.
- W3042361689 isRetracted "false" @default.
- W3042361689 magId "3042361689" @default.
- W3042361689 workType "article" @default.